Alector
1 known investors
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
AI & Machine LearningBiotechHealthtechLongevityMedical Devices
Founders & leadership
AR
Arnon RosenthalPh.D.
Investors · 1
In the news
- Alector (NASDAQ:ALEC) Shares Up 7.9% – What’s Next? - Daily Politicaldailypolitical.com · 2026
- Weekly News Roundup | 13 July 2026 | Life Science Daily Newslifesciencedaily.news · 2026
- Alector raises $133 million in Series E round for neurology drug development - MedCity Newsmedcitynews.com · 2018